Infliximab treatment for chronic sarcoidosis - A case series;Infliximab et sarcoïdose chronique. L'expérience française à propos de 31 cas

Revue des Maladies Respiratoires

Volumn 27, Issue 7, 2010, Pages 685-692

  Jounieaux, F ^a   Chapelon, C ^b   Valeyre, D ^c   Israel Biet, D ^d   Cottin, V ^e   Tazi, A ^f   Fournier, E ^g   Wallaert, B ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e UMR 754   (France)

^f Services de Pneumologie Phtisiologie   (France)

^g Polyclinique d'Hénin Beaumont ^*  (France)

Author keywords

Anti TNF ; Chronic disease; Infliximab; Sarcoidosis; Steroids; Treatment

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PREDNISOLONE;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; LUNG SARCOIDOSIS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SARCOIDOSIS; SKIN DEFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049276668     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmr.2010.06.011     Document Type: Article

References (49)

1. R.P. Baughman E.E. Lower R.M. du Bois Sarcoidosis Lancet 361 2003 1111 1118
2. American Thoracic Society Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999 Am J Respir Crit Care Med 160 1999 736 755
3. M. Miyara Z. Amoura C. Parizot C. Badoual K. Dorgham S. Trad, et al. The immune paradox of sarcoidosis and regulatory T cells J Exp Med 203 2006 359 370
4. D.R. Roach A.G. Bean C. Demangel M.P. France H. Briscoe W.J. Britton TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection J Immunol 168 2002 4620 4627
5. R.N. Serio Infliximab treatment of sarcoidosis Ann Pharmacother 37 4 2003 577 581
6. N. Myatt G. Coghill K. Morrison D. Jones I.A. Cree Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation J Clin Pathol 47 1994 423 426
7. M. Steffen J. Petersen M. Oldigs A. Karmeier H. Magnussen H.G. Thiele, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis J Allergy Clin Immunol 91 1993 939 949
8. H. Dai J. Guzman B. Chen U. Costabel Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis Chest 127 2005 251 256
9. S.D. Roberts D.S. Wilkes R.A. Burgett K.S. Knox Refractory sarcoidosis responding to infliximab Chest 124 2003 2028 2031
10. J.D. Doty J.E. Mazur M.A. Judson Treatment of sarcoidosis with infliximab Chest 127 2005 1064 1071
11. N.J. Sweiss M.J. Welsch J.J. Curran M.H. Ellman Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis Arthritis Rheum 53 2005 788 791
12. A.M. Yee M.B. Pochapin Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy Ann Intern Med 135 2001 27 31
13. S. Saleh S. Ghodsian V. Yakimova J. Henderson O.P. Sharma Effectiveness of infliximab in treating selected patients with sarcoidosis Respir Med 100 2006 2053 2059
14. N. Milman T.B. Sorensen Treatment of severe sarcoidosis using TNF-alpha-inhibitor (infliximab) Ugeskr Laeger 168 2006 484 485
15. S.M. Fouchier G.M. Moller M. Van Santen-Hoeufft C.G. Faber F.W. Smeenk M. Drent Successful treatment with infliximab of a patient with refractory sarcoidosis Ned Tijdschr Geneeskd 148 2004 2446 2450
16. C. Pritchard K. Nadarajah Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients Ann Rheum Dis 63 2004 318 320
17. K.U. Ulbricht M. Stoll J. Bierwirth T. Witte R.E. Schmidt Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis Arthritis Rheum 48 2003 3542 3543
18. T.M. O'Connor F. Shanahan C.P. Bredin Infliximab therapy for complicated sarcoidosis Ann Intern Med 137 2002 296 297 [author reply 296-7]
19. M.C. Cook Infliximab therapy for complicated sarcoidosis Ann Intern Med 137 2002 296 297 [author reply 296-7]
20. R.P. Baughman E.E. Lower Infliximab for refractory sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 18 2001 70 74
21. R.P. Baughman M. Drent M. Kavuru M.A. Judson U. Costabel R. du Bois, et al. Sarcoidosis Investigators Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement Am J Respir Crit Care Med 174 2006 795 802
22. A.F. Alexis B.E. Strober Off-label dermatologic uses of anti-TNF-a therapies J Cutan Med Surg 9 2005 296 302
23. M.P. Heffernan M.J. Anadkat Recalcitrant cutaneous sarcoidosis responding to infliximab Arch Dermatol 141 2005 910 911
24. H. Haley W. Cantrell K. Smith Infliximab therapy for sarcoidosis (lupus pernio) Br J Dermatol 150 2004 146 149
25. L. Mallbris A. Ljungberg M.A. Hedblad P. Larsson M. Stahle-Backdahl Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy J Am Acad Dermatol 48 2003 290 293
26. Baughman RP, Lower EE, Judson MA, Teirstein A, Schlenker-Herceg R, Barnathan E. Lupus pernio in sarcoidosis: clinical features and a target for therapy. Presented at the American Thoracic Society International Conference; May 20-25, 2005; San Diego, CA.
27. J.H. Meyerle A. Shorr The use of infliximab in cutaneous sarcoidosis J Drugs Dermatol 2 2003 413 414
28. F. Baert M. Noman S. Vermeire G. Van Assche G. D' Haens A. Carbonez, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 2003 601 608 (Pubitemid 36204954)
29. S. Candon A. Mosca F. Ruemmele O. Goulet L. Chatenoud J.P. Cezard Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease Clin Immunol 118 2006 11 19
30. G. Valesini C. Lannuccelli E. Marocchi L. Pascoli V. Scalzi M. Di Franco Biological and clinical effects of anti-TNFalpha treatment Autoimmun Rev 7 2007 35 41
31. A. Kavanaugh E.W. Clair W.J. McCune, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy J Rheumatol 27 2000 841 850
32. A.F. Edrees S.N. Misra N.I. Abdou Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions Clin Exp Rheumatol 23 2005 469 474
33. R.N. Maini F.C. Breedveld J.R. Kalden, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552 1563
34. R.P. Baughman E.E. Lower M. Drent Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them Sarcoidosis Vasc Diffuse Lung Dis 25 2008 76 89
35. M.A. Judson R.P. Baughman U. Costabel S. Flavin K.H. Lo M.S. Kavuru, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Centocor T48 Sarcoidosis Investigators Eur Respir J 31 2008 1189 1196
36. M.D. Rossman L.S. Newman R.P. Baughman A. Teirstein S.E. Weinberger W. Miller Jr., et al. A double-blinded, randomized, placebo-controlled trial in subjects with active pulmonary sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 23 2006 201 208
37. C. Miceli-Richard E. Comets C. Verstuyft R. Tamouza P. Loiseau P. Ravaud, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis Ann Rheum Dis 67 2008 478 484
38. M. Veltkamp P.A. Wijnen C.H. van Moorsel G.T. Rijkers H.J. Ruven M. Heron, et al. Linkage between Toll-like receptor (TLR) 2 promotor and intron polymorphisms: functional effects and relevance to sarcoidosis Clin Exp Immunol 149 2007 453 462
39. S. Sharma B. Ghosh S.K. Sharma Association of TNF polymorphisms with sarcoidosis, its prognosis and tumor necrosis factor(TNF)-alpha levels in Asian Indians Clin Exp Immunol 151 2008 251 259
40. J. Grunewald Genetics of sarcoidosis Curr Opin Pulm Med 14 2008 434 439
41. I. Medica A. Kastrin A. Maver B. Peterlin Role of genetic polymorphisms in ACE and TNF-alpha gene in sarcoidosis: a meta-analysis J Hum Genet 52 2007 836 847
42. R. Dhote S. Abad D. Valeyre Complications infectieuses de la sarcoïdose Presse Med 38 2009 317 323
43. J. Keane S. Gershon R.P. Wise, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 2001 1098 1104
44. D.E. Furst R. Wallis M. Broder D.O. Beenhouwer Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection Semin Arthritis Rheum 36 2006 159 167
45. M.P. Moiton C. Richez C. Dumoulin N. Mehsen J. Dehais T. Schaeverbeke Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections Clin Microbiol Infect 12 2006 1151 1153
46. D. Salmon-Ceron Groupe recherche anti-TNF et infections opportunistes Agence francaise de sécurité sanitaire des produits de santé Recommendations for the prevention and management of tuberculosis in patients taking infliximab Ann Med Interne (Paris) 153 2002 429 431
47. E. Toussirot E. Pertuiset B. Kantelip D. Wendling Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases Clin Exp Rheumatol 26 2008 471 475
48. R. Almodóvar M. Izquierdo P. Zarco F. Javier Quirós R. Mazzucchelli B. Steen Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab Clin Exp Rheumatol 25 2007 99 101
49. A. Massara L. Cavazzini R. La Corte F. Trotta Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "Class Effect" paradoxical phenomenon. Two case reports and litterature review Semin Arthritis Rheum 39 2010 313 319